Results 41 to 50 of about 8,906 (137)

Medical regimens for abortion at 12 weeks and above: a systematic review and meta-analysis

Contraception: X, 2020
Background: Mifepristone and misoprostol are recommended for second-trimester medical abortion, but consensus is unclear on the ideal regimen. Objectives: The objectives were to systematically review randomized controlled trials (RCTs) investigating ...
Katherine Whitehouse, Ashley Brant, Marita Sporstol Fonhus, Antonella Lavelanet, Bela Ganatra   +4 more
doaj   +1 more source

Educating Midwives as Abortion Providers: Implementing Innovative Models for Standardized Training in Abortion Care

Journal of Midwifery &Women's Health, EarlyView.
Abstract The Dobbs v Jackson Women's Health Organization US Supreme Court decision significantly limited patients' access to abortion services, and the providers who can legally deliver this care. Currently 22 states license providers other than physicians to provide medication or procedural abortion.
Nicole Quinones, Samantha Auerbach, Nikki Lanshaw, Nikia Grayson, Julie Blumenfeld, Becca Neuwirth, Pamela Pearson, Ellen Chaney Solis, Robyn Nisi, Kylea L. Liese   +9 more
wiley   +1 more source

A prospective study on the effectiveness of a combination regime (Mifepristone and Misoprostol) in comparison with Misoprostol for missed abortion

Journal of Family Medicine and Primary Care, 2023
Introduction: Misoprostol is widely used in the medical management of missed abortions. However, pretreatment with Mifepristone has shown to be effective but still not recommended to be used in missed abortions.
Nidhi Gupta, Reva Tripathi, Sumedha Sharma, Aruna Nigam, Sanjeet Panesar   +4 more
doaj   +1 more source

C‐X‐C chemokine receptor CXCR4 mediates diurnal changes in the aggregation and dispersion of CD8+ T cells within the tumor microenvironment

International Journal of Cancer, Volume 158, Issue 6, Page 1740-1754, 15 March 2026.
What's new? In addition to governing daily variations in biological activity, the circadian clock regulates immune cell migration into tumors. Whether this influence extends to immune cell localization within the tumor microenvironment (TME) is unknown. Here, using cell and animal models, the authors investigated immune cell distribution within the TME
Akito Tsuruta, Marina Fujimoto, Yasuha Hiraoka, Aoi Taniguchi, Yuki Shiiba, Takuto Inoki, Tomoaki Yamauchi, Yuya Yoshida, Naoya Matsunaga, Shigehiro Ohdo, Satoru Koyanagi   +10 more
wiley   +1 more source

Mifepristone Followed by Misoprostol Compared with Placebo Followed by Misoprostol as Medical Treatment for Early Pregnancy Loss (the Triple M trial): A Double-Blind Placebo-Controlled Randomised Trial

Fertility & Reproduction, 2022
Background: Worldwide, millions of women seek treatment for early pregnancy loss (EPL) annually. Medical management with misoprostol is widely used, but only effective 60% of the time.
Charlotte HAMEL, Sjors COPPUS, Joyce VAN DEN BERG, Esther HINK, Jacoba VAN SEETERS, Paul VAN KESTEREN, Ashley MERIEN, Bas TORRENGA, Rafli VAN DE LAAR, Josien Terwisscha VAN SCHELTINGA, Ingrid GAUGLER-SENDEN, Peppino GRAZIOSI, Minouche VAN RUMSTE, Ewka NELISSEN, Frank VANDENBUSSCHE, Marcus SNIJDERS   +15 more
doaj   +1 more source

Mifepristone therapy in symptomatic leiomyomata using a variable dose pattern with a favourable outcome

Journal of Mid-Life Health, 2018
Background: Leiomyomata causing symptoms have a deleterious effect on the health of women during reproductive age. Mifepristone, a progesterone antagonist was studied for reduction of symptoms in leiomyomata in perimenopausal women. Material and Methods:
Deepti Jain
doaj   +1 more source

Efficacy and Tolerability of Metyrapone in Mild Autonomous Cortisol Secretion: Real‐World Findings From Clinical Practice

Clinical Endocrinology, Volume 104, Issue 3, Page 215-221, March 2026.
ABSTRACT Objective Mild autonomous cortisol secretion (MACS) is associated with increased cardiometabolic risk factors including hypertension, type 2 diabetes and dyslipidaemia. By using evening doses of metyrapone, a short‐acting 11‐β hydroxylase inhibitor, it has been shown that it is possible to reset the abnormal circadian cortisol rhythm in MACS ...
Simon Berry, Ahmed Iqbal, John Newell‐Price, Miguel Debono   +3 more
wiley   +1 more source

Development of specific glucocorticoid receptor antagonists

European Journal of Psychotraumatology, 2012
Background / Methods : Mifepristone, a potent glucocorticoid receptor (GR) and progesterone receptor (PR) antagonist, has recently become the first medication approved for the treatment of Cushing's syndrome, the archetypal illness of cortisol ...
Joseph K. Belanoff
doaj   +1 more source

The immunological effect of Galectin-9/TIM-3 pathway after low dose Mifepristone treatment in mice at 14.5 day of pregnancy. [PDF]

PLoS ONE, 2018
The abortifacient Mifepristone (RU486) has proven to be a safe, effective, acceptable option for millions of women seeking abortion during the first and second trimester of pregnancy although its precise mechanism of action is not well understood.
Adrienn Lajko, Matyas Meggyes, Beata Polgar, Laszlo Szereday   +3 more
doaj   +1 more source

Use of point‐of‐care ultrasound in the diagnosis of uterine rupture

Ultrasound in Obstetrics &Gynecology, EarlyView.
S. Tartaglia, C. Neri, M. A. Policriti, C. Riccetti, A. Familiari, T. Ghi   +5 more
wiley   +1 more source